Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma

BACKGROUND: Bortezomib is an approved proteasome inhibitor for the treatment of certain lymphoma subtypes. Two clinical trials investigated bortezomib in patients with malignant pleural mesothelioma (MPM) and failed to improve outcome. We present a potential explanation for this event. METHODS: 171...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Manag Res
Päätekijät: Walter, Robert Fred Henry, Sydow, Saskia Roxanne, Berg, Erika, Kollmeier, Jens, Christoph, Daniel Christian, Christoph, Sandra, Eberhardt, Wilfried Ernst Erich, Mairinger, Thomas, Wohlschlaeger, Jeremias, Schmid, Kurt Werner, Mairinger, Fabian Dominik
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove 2019
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6765394/
https://ncbi.nlm.nih.gov/pubmed/31576173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S194337
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia